Cargando…
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
OBJECTIVE: A Phase 3 open‐label safety study (NCT02721069) evaluated long‐term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters. METHODS: Patients were 6–65 years old with diagnosed epilepsy and seizure clusters despite stable antiseizure medications....
Autores principales: | Wheless, James W., Miller, Ian, Hogan, R. Edward, Dlugos, Dennis, Biton, Victor, Cascino, Gregory D., Sperling, Michael R., Liow, Kore, Vazquez, Blanca, Segal, Eric B., Tarquinio, Daniel, Mauney, Weldon, Desai, Jay, Rabinowicz, Adrian L., Carrazana, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290500/ https://www.ncbi.nlm.nih.gov/pubmed/34418086 http://dx.doi.org/10.1111/epi.17041 |
Ejemplares similares
-
Consistent safety and tolerability of Valtoco(®) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study
por: Miller, Ian, et al.
Publicado: (2021) -
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long‐term, open‐label safety study
por: Segal, Eric B., et al.
Publicado: (2021) -
Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study
por: Sperling, Michael R., et al.
Publicado: (2022) -
Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study
por: Hogan, Robert Edward, et al.
Publicado: (2020) -
Lack of clinically relevant differences in safety and pharmacokinetics after second‐dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis
por: Cascino, Gregory D., et al.
Publicado: (2022)